Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05219799 · ClinicalTrials.gov registry record · Early Phase 1
Sex Disparities in Hypoxic Vasodilation and Impact of Obesity
A Early Phase 1 study of Healthy and Obesity, sponsored by University of Missouri-Columbia.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 72
- Enrollment target
- 1
- Study location
NCT05219799: Recruiting Early Phase 1 study of Healthy and Obesity, sponsored by University of Missouri-Columbia.
NCT05219799 is a Early Phase 1 study of Healthy and Obesity that is actively recruiting participants, run by University of Missouri-Columbia. The registered enrollment target is 72 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05219799, a Early Phase 1 study of Healthy and Obesity, is actively recruiting participants, sponsored by University of Missouri-Columbia.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 72 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this project is to examine key mechanisms contributing to sex-differences in hypoxic vasodilation and the impact of obesity, with particular emphasis on the sympathetic nervous system.
Primary Outcome
Vascular conductance is an index of vascular tone and is measured using a technique called venous occlusion plethysmography.
Conditions Studied
Interventions
- DRUG Norepinephrine
- DRUG Isoproterenol
- DRUG Propranolol Hydrochloride
- DRUG Phentolamine Mesylate
Study Locations (1)
Missouri
- University of Missouri - Columbia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2023-03-14 |
| Est. Completion | 2026-06-30 |
| Phase | Early Phase 1 |
What NCT05219799 shows while recruiting
NCT05219799 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 72 participants, a relatively small participant target, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (89% lower).
The record links to 3 conditions, with Healthy appearing as the primary indexed condition, and to 4 interventions - of which Norepinephrine is the first listed.
NCT05219799 reports a single indexed study location in Missouri.
Frequently Asked Questions
What is clinical trial NCT05219799 about?
NCT05219799 is a clinical study titled "Sex Disparities in Hypoxic Vasodilation and Impact of Obesity". The purpose of this project is to examine key mechanisms contributing to sex-differences in hypoxic vasodilation and the impact of obesity, with particular emphasis on the sympathetic nervous system.
What is the current status of trial NCT05219799?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 72 participants. The study started on 2023-03-14. Estimated completion is 2026-06-30.
What conditions does trial NCT05219799 study?
This clinical trial studies the following conditions: Healthy, Obesity, Vasodilation.
What interventions are being tested in trial NCT05219799?
The interventions under investigation include: Norepinephrine (DRUG), Isoproterenol (DRUG), Propranolol Hydrochloride (DRUG), Phentolamine Mesylate (DRUG).
Who is sponsoring clinical trial NCT05219799?
This trial is sponsored by University of Missouri-Columbia, which has 291 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05219799 being conducted?
This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05219799's enrollment target sits among peer trials
72 314th of 1090 higher than 770 of 1,090 other Healthy trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Healthy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mapping Auricular Vagus Nerve Circuitry
RECRUITING · Early Phase 1
-
Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
RECRUITING · Early Phase 1
-
SV2A Density Cannabis Use Disorder
RECRUITING · Early Phase 1
-
CBD-Microglia PET Study
RECRUITING · Early Phase 1
-
Positron Emission Tomography (PET) Contrast Agent Kinetics and Safety: [18F]-Fluoromannitol
RECRUITING · Early Phase 1
-
Study to Assess the Safety, Tolerability, PK and PD of ABX1100
ACTIVE NOT RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02359253 · 72 participants · NA
Robot Aided Rehabilitation - Intervention
- NCT02962661 · 72 participants · Phase 1
Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients With Cardiomyopathy Caused by Anthracyclines
- NCT03113643 · 72 participants · Phase 1
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- NCT03187535 · 72 participants · NA
Effect of TEAS on PONV After Spinal Surgery
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI